<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04092244</url>
  </required_header>
  <id_info>
    <org_study_id>CTHRC1 in rheumatoid disease</org_study_id>
    <nct_id>NCT04092244</nct_id>
  </id_info>
  <brief_title>Role of CTHRC1 in Diagnosis of Rheumatoid Arthritis</brief_title>
  <official_title>CTHRC1 as a New Biomarker in Diagnosis of Rheumatoid Arthritis and Its Role in Seronegative Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to detect the role of CTHRC1 biomarker in diagnosis of rheumatoid arthritis and To correlate
      other well-established rheumatoid arthritis markers (RF&amp; anti-ccp) and CTHRC1 level to see if
      CTHRC1 can act as a dependent or independent serum marker in prediction of RA status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints.
      Disease progression is characterized by periods of high disease activity involving both, a
      systemic immune response and tissue-specific inflammatory events that may lead to joint and
      bone destruction and subsequent disability.

      Rheumatoid arthritis is a multifactorial disease with significant contribution from genetic
      and non-genetic factors that together account for complex disease pathology.

      Diagnosis of RA is based mainly on detection of high titers of rheumatoid factor (RF) and of
      antibodies against cyclic citrullinated peptide (anti-CCP) or against citrullinated protein
      (ACPA).

      The major RF species could be detected only in 60-70% of RA patients; patients with high
      levels of RF have higher disease activity with greater disabilities.

      The problem is that RF is not a specific marker for RA and is often absent in early stages of
      the disease, on the other hand ACPA and CCP auto antibodies provide high specificity but
      moderate sensitivity, adding to that CRP and ESR are general indicators of inflammation and
      are not specific for RA.

      Collagen triple helix repeat containing 1 protein (CTHRC1) is expressed in a number of
      embryonic and neonate tissues, including developing cartilage and bone. It is a secreted
      modulator of Wnt signaling, which is a key regulator of joint remodeling and promotes cell
      proliferation and migration.

      Immunohistochemical analysis of various human primary cancers and metastases has revealed
      that CTHRC1 expression is actually limited to the stromal cells of solid tumors.

      The expression of CTHRC1 encoding gene was found to be strongly associated with the severity
      of murine collagen antibody-induced arthritis.

      Arthritic pannus is a multicellular vascularized tissue composed of cells of both mesenchymal
      and hematopoietic origin, including synovial fibroblasts, osteoclasts, endothelial cells,
      dendritic cells, monocytes/macrophages, as well as T and B cells that contribute to the
      development and progression of joint and cartilage erosion through secretion of
      pro-inflammatory cytokines and tissue-degrading proteases. Fibroblast-like synoviocytes
      (FLS), particularly the invasive and migratory cadherin-11-positive subtype, are major
      components of synovial pannus tissue and are considered active drivers in the pathogenesis of
      RA.

      The expression of CTHRC1 in pannus and its role in the function of FLS relevant to cartilage
      damage in RA make it of great value if used as a blood-based biomarker for improved diagnosis
      of rheumatoid arthritis patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>detect value of CTHRC1 in diagnosis of rheumatoid arthritis</measure>
    <time_frame>baseline</time_frame>
    <description>detect the role of CTHRC1 biomarker in diagnosis of rheumatoid arthritis and To compare the sensitivity and the specificity of CTHRC1 in relation to other biomarkers used in diagnosis of RA.</description>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CTHRC1 biomarker</intervention_name>
    <description>its a biomarker detected in the serum of the patients</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include the following:

          -  35 RA patients with negative anti_ccp.

          -  35 RA patients with negative RF.

          -  45 RA patients either positive RF or anti-ccp.

          -  30 other Arthritic patients.

          -  25 healthy controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All RA patients must fulfill the 2010 ACR/EULAR criteria for RA.

          -  Healthy individual must be without a prior history of chronic inflammation or any form
             of arthritis.

        Exclusion Criteria:

          -  - Patients with solid tumors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>amany hefny</last_name>
    <phone>+201001545631</phone>
    <email>amany011108@med.aun.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>sohair kamel</last_name>
    <phone>+201024477711</phone>
    <email>ksoher3@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.</citation>
    <PMID>29417936</PMID>
  </reference>
  <reference>
    <citation>Shekhani MT, Forde TS, Adilbayeva A, Ramez M, Myngbay A, Bexeitov Y, Lindner V, Adarichev VA. Collagen triple helix repeat containing 1 is a new promigratory marker of arthritic pannus. Arthritis Res Ther. 2016 Jul 19;18:171. doi: 10.1186/s13075-016-1067-1.</citation>
    <PMID>27430622</PMID>
  </reference>
  <reference>
    <citation>Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2010 Mar;103(3):139-46. doi: 10.1093/qjmed/hcp165. Epub 2009 Nov 19. Review.</citation>
    <PMID>19926660</PMID>
  </reference>
  <reference>
    <citation>Singal DP, Li J, Zhu Y. Genetic basis for rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 1999;47(5):307-11. Review.</citation>
    <PMID>10604236</PMID>
  </reference>
  <reference>
    <citation>Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005 Dec;64(12):1731-6. Epub 2005 May 5.</citation>
    <PMID>15878904</PMID>
  </reference>
  <reference>
    <citation>Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schnäker EM, Tarner IH, Robbins PD, Evans CH, Stürz H, Steinmeyer J, Gay S, Schölmerich J, Pap T, Müller-Ladner U, Neumann E. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009 Dec;15(12):1414-20. doi: 10.1038/nm.2050. Epub 2009 Nov 8.</citation>
    <PMID>19898488</PMID>
  </reference>
  <reference>
    <citation>Han B, Pouget JG, Slowikowski K, Stahl E, Lee CH, Diogo D, Hu X, Park YR, Kim E, Gregersen PK, Dahlqvist SR, Worthington J, Martin J, Eyre S, Klareskog L, Huizinga T, Chen WM, Onengut-Gumuscu S, Rich SS; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Wray NR, Raychaudhuri S. A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases. Nat Genet. 2016 Jul;48(7):803-10. doi: 10.1038/ng.3572. Epub 2016 May 16.</citation>
    <PMID>27182969</PMID>
  </reference>
  <reference>
    <citation>Durmus T, LeClair RJ, Park KS, Terzic A, Yoon JK, Lindner V. Expression analysis of the novel gene collagen triple helix repeat containing-1 (Cthrc1). Gene Expr Patterns. 2006 Oct;6(8):935-40. Epub 2006 Mar 17.</citation>
    <PMID>16678498</PMID>
  </reference>
  <reference>
    <citation>Ding B, Padyukov L, Lundström E, Seielstad M, Plenge RM, Oksenberg JR, Gregersen PK, Alfredsson L, Klareskog L. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum. 2009 Jan;60(1):30-8. doi: 10.1002/art.24135. Erratum in: Arthritis Rheum. 2009 Apr;60(4):1200.</citation>
    <PMID>19116921</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amany Abdelkader Ahmed Hefny</investigator_full_name>
    <investigator_title>Resident physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

